Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
3/5 보강
TL;DR
Dato-DXd plus pembrolizumab therapy (with and without Pt-CT) exhibited appreciable safety and durable antitumor activity across PD-L1 expression levels in patients with amNSCLC.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
142 patients received doublet (n = 70) or triplet (n = 72) therapy; 96 were treatment-naive (doublet: n = 42; triplet: n = 54).
I · Intervention 중재 / 시술
doublet (n = 70) or triplet (n = 72) therapy; 96 were treatment-naive (doublet: n = 42; triplet: n = 54)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Dato-DXd plus pembrolizumab therapy (with and without Pt-CT) exhibited appreciable safety and durable antitumor activity across programmed death-ligand 1 expression levels in patients with advanced or metastatic NSCLC. [CLINICAL TRIAL INFORMATION] ClinicalTrials.gov Identifier: NCT04526691.
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations
Lung Cancer Research Studies
Dato-DXd plus pembrolizumab therapy (with and without Pt-CT) exhibited appreciable safety and durable antitumor activity across PD-L1 expression levels in patients with amNSCLC.
- 표본수 (n) 70
APA
Benjamin Levy, Luis Paz-Ares, et al. (2026). Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 103688. https://doi.org/10.1016/j.jtho.2026.103688
MLA
Benjamin Levy, et al.. "Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026, pp. 103688.
PMID
41871716 ↗
Abstract 한글 요약
[INTRODUCTION] The phase Ib two-part (dose escalation and expansion) six-cohort TROPION-Lung02 study evaluated datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum-based chemotherapy (Pt-CT) in patients with advanced or metastatic NSCLC without actionable genomic alterations.
[METHODS] Patients received Dato-DXd (4 or 6 mg/kg) plus pembrolizumab 200 mg alone (doublet) or with Pt-CT (triplet; carboplatin AUC 5 or cisplatin 75 mg/m) once every 3 weeks. The primary objective was safety and tolerability; efficacy was a secondary objective. Exploratory biomarker analyses assessing TROP2 normalized membrane ratio by quantitative continuous scoring were performed in the treatment-naive patient subset.
[RESULTS] In total, 142 patients received doublet (n = 70) or triplet (n = 72) therapy; 96 were treatment-naive (doublet: n = 42; triplet: n = 54). Grade 3 or higher treatment-related adverse events occurred in 37.1% (doublet) and 59.7% (triplet) of patients. No treatment-related deaths occurred. In treatment-naive patients receiving doublet therapy, the confirmed objective response rate was 54.8%, the median duration of response was 20.1 months, and the median progression-free survival was 11.2 months. With triplet therapy, the confirmed objective response rate was 55.6%, the median duration of response was 13.7 months, and the median progression-free survival was 6.8 months. Tumor responses were observed across programmed death-ligand 1 expression levels for both regimens. Exploratory TROP2 normalized membrane ratio biomarker analyses revealed trends toward improved survival outcomes in patients who were biomarker-positive compared with biomarker-negative.
[CONCLUSION] Dato-DXd plus pembrolizumab therapy (with and without Pt-CT) exhibited appreciable safety and durable antitumor activity across programmed death-ligand 1 expression levels in patients with advanced or metastatic NSCLC.
[CLINICAL TRIAL INFORMATION] ClinicalTrials.gov Identifier: NCT04526691.
[METHODS] Patients received Dato-DXd (4 or 6 mg/kg) plus pembrolizumab 200 mg alone (doublet) or with Pt-CT (triplet; carboplatin AUC 5 or cisplatin 75 mg/m) once every 3 weeks. The primary objective was safety and tolerability; efficacy was a secondary objective. Exploratory biomarker analyses assessing TROP2 normalized membrane ratio by quantitative continuous scoring were performed in the treatment-naive patient subset.
[RESULTS] In total, 142 patients received doublet (n = 70) or triplet (n = 72) therapy; 96 were treatment-naive (doublet: n = 42; triplet: n = 54). Grade 3 or higher treatment-related adverse events occurred in 37.1% (doublet) and 59.7% (triplet) of patients. No treatment-related deaths occurred. In treatment-naive patients receiving doublet therapy, the confirmed objective response rate was 54.8%, the median duration of response was 20.1 months, and the median progression-free survival was 11.2 months. With triplet therapy, the confirmed objective response rate was 55.6%, the median duration of response was 13.7 months, and the median progression-free survival was 6.8 months. Tumor responses were observed across programmed death-ligand 1 expression levels for both regimens. Exploratory TROP2 normalized membrane ratio biomarker analyses revealed trends toward improved survival outcomes in patients who were biomarker-positive compared with biomarker-negative.
[CONCLUSION] Dato-DXd plus pembrolizumab therapy (with and without Pt-CT) exhibited appreciable safety and durable antitumor activity across programmed death-ligand 1 expression levels in patients with advanced or metastatic NSCLC.
[CLINICAL TRIAL INFORMATION] ClinicalTrials.gov Identifier: NCT04526691.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: a result from Korea post-marketing surveillance.
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
- Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).